ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

"Advancements in the Diagnosis and Treatment of Hepatorenal Syndrome: The Role of Modern Medical Technologies"

Jabbarov Azimboy Ataxonovich

Professor at Head of department of faculty and hospital therapy Tashkent Medical Academy, Tashkent Medical Academy, Uzbekistan, (doctor.azim.jabborov@gmail.com)

Anagul Samadova

Assistant at Urgench Branch of Tashkent Medical Academy, department of internal disease at regional hospital of Khorezm region, Urgench, Uzbekistan. (samadovaanagul756@gmail.com)

Dinaliyeva Dina Maratovna

Assistant at Urgench Branch of Tashkent Medical Academy, department of Microbiology,virusology and immunology , Urgench, Uzbekistan.

(dinara.dinarochka1@gmail.com)

Abstract. *Hepatorenal syndrome is a significant medical condition that highlights the intricate connection between liver and kidney functions. This article discusses the relevance of incorporating advanced medical technologies and techniques in the treatment of hepatorenal syndrome. Contemporary medical advancements, including targeted therapies, regenerative medicine, and novel biomarkers, play a crucial role in enhancing the efficacy of hepatorenal syndrome management. The study points out potential improvements in clinical outcomes through the adoption of innovative treatment practices and approaches. The article seeks to offer top-quality medical care to patients by utilizing modern diagnostic techniques and personalized strategies. The application of new technologies can enhance the quality of life and extend the longevity of individuals suffering from hepatorenal syndrome.*

Keywords: *Hepatorenal syndrome, Cystotin C, liver cirrhosis,kidney dysfunction , urinary albumin, creatinine, dialysis, alternatives,*

Introduction.

Hepatorenal Syndrome (HRS) is a condition resulting from severe liver failure and portal hypertension in patients with acute or chronic liver disease. It is caused by various other factors, such as the use of nephrotoxic drugs, urinary tract obstruction, chronic kidney disease, and others, which can lead to kidney damage. Morphologically, kidneys in HRS remain almost unchanged, with a decrease in the number of mesangial cells, except in certain cases [1]. Hepatorenal syndrome is often associated with ascites, usually seen in alcoholic cirrhosis, and can complicate acute hepatitis, liver or biliary tract surgery, obstructive jaundice (referred to as "surgical" hepatorenal syndrome), liver tumors, and other conditions. It may also result from decreased circulatory blood volume (due to excessive doses of diuretics, prolonged diarrhea, persistent vomiting, or large-volume fluid removal during paracentesis without proper albumin replacement therapy), the use of steroids and non-steroidal anti-inflammatory drugs, nephrotoxic drugs (such as aminoglycosides, cyclosporine), blood

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

loss (from bleeding varices of the esophagus or intestines), infections, or excessive alcohol consumption [1].

Importance: In recent years, the issue of hepatorenal syndrome has gained significant attention from doctors due to its seriousness. Until this period, it had remained under the shadow of other diseases with more social significance. Interest in the effects of liver cirrhosis grew in the early 2000s, particularly after large epidemiological studies revealed high frequencies of kidney dysfunction in patients with liver disease and the recognition that the global expansion of hemodialysis services was not enough to address this issue. Consequently, the number of patients with kidney failure (KF) has been steadily increasing.

During cirrhosis, despite a progressive increase in the concentration of renin and norepinephrine in plasma, arterial vasodilation intensifies. Despite progressive stimulation of the sympathetic nervous system, the heart rate does not increase. This suggests that in cirrhosis, circulatory dysfunction is not only due to the development of arterial vasodilation, but also related to the inability of the heart to increase cardiac output in response to reduced preload [1, 4, 6].

Materials and Methods: Our research is based on the results of laboratory and instrumental examinations of 90 patients with liver cirrhosis and 30 healthy controls.
The study included two groups: one group of patients with liver cirrhosis who had kidney dysfunction (n=45) and another group of patients with liver cirrhosis without kidney dysfunction (n=45). All patients involved in the study underwent laboratory and instrumental examinations.

The 90 patients with liver cirrhosis were divided into two main groups based on the "case-control" principle:

1. **Group 1**: Patients with liver cirrhosis who did not develop kidney dysfunction (n=45). Male n=22 (49%), Female n=23 (51%), Average age = 42.5.
2. **Group 2**: Patients with liver cirrhosis who developed kidney dysfunction (n=45). Male n=27 (60%), Female n=18 (40%), Average age = 50.3.

In the research, patients with liver cirrhosis who developed kidney dysfunction and those who did not develop kidney dysfunction were subjected to the following clinical and biochemical tests:

- Microalbuminuria (MAU), blood levels of ALT, AST, bilirubin, cystatin C, creatinine, urea, cholesterol (TC), triglycerides (TGL), high-density and low-density lipoproteins (HDL, LDL), glomerular filtration rate (GFR), Doppler ultrasound of renal vessels (RVD), liver elastography (FibroScan). The glomerular filtration rate (GFR) was measured using the CKD-EPI (ml/min/1.73m^2) formula.

The collected data were processed statistically using the MS Excel (2010) software. The means and standard deviations (M±m) of all the indicators presented in the tables were calculated. The differences between the groups were evaluated for statistical significance using the Student's t-test, with a significance level set at $p<0.05$.

Results and Discussion: The comparison of the 1st and 2nd groups of patients showed significant differences in renal function. We found that in the 2nd group (patients with kidney dysfunction), there

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

was a significantly higher level of microalbuminuria (MAU) compared to the 1st group (31.37±2.37 vs. 90.35±17.21).

Furthermore, an increase in MAU levels in urine correlated positively with higher blood urea (r=0.36), creatinine (r=0.40), and the resistance index (RI) from Doppler ultrasound of the renal vessels, indicating a strong and significant positive relationship.

Table 1
Laboratory Indicators

Indicator	Group 1	Group 2
Age	42.5±0.83	50.5±2.85
MAU	30.27±2.47	91.56±18.11*
ALT	56.2±2.32	52.4±2.47*
AST	52.3±0.27	49.6±0.81*
Cystatin C	2.43±0.18	7.16±0.80*
Urea	4.32±0.21	9.01±0.82*
Creatinine	68.8±2.36	141.67±21.25*
GFR	91.14±3.08	45.6±70.55*
Cholesterol	3.9±0.17	5.1±0.12*
Triglycerides	1.71±0.43	3.41±0.19
LDL	3.07±0.14	3.54±0.08*
HDL	1.17±0.05	0.93±0.05

Note: * - Statistically significant ($p<0.05$).

Discussion of Results: In the study of kidney function, we examined the blood urea, creatinine, and GFR levels. When comparing the results of the 1st and 2nd groups, we observed a significant decrease in kidney function in the 2nd group (patients with kidney dysfunction) compared to the 1st group, with a GFR of 91.14±3.08 vs. 45.6±70.55. Increased levels of blood urea and creatinine were associated with a decrease in GFR. A strong positive correlation was found between urea and creatinine levels (r=0.85), while a negative correlation was found between urea and GFR (r=-0.84) and between creatinine and GFR (r=-0.84).

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

Furthermore, there was a significant negative correlation between renal vascular resistance index (RI) (r=-0.62) and pulsatility index (PI) (r=-0.34). A positive correlation was observed between GFR and cholesterol (r=0.67) and triglycerides (r=0.25).

These results suggest that kidney dysfunction in patients with liver cirrhosis leads to deterioration of kidney function. In Table 1 and 2, when cystatin C was analyzed, a higher level was observed in the 2nd group compared to the 1st group. Increased cystatin C levels were correlated with a decrease in renal circulation, indicated by a negative correlation with the maximum blood flow velocity (Vmax) (r=-0.28) and GFR (r=-0.28).

Conclusion:

Thus, both hemodynamic and metabolic factors independently contribute to the characteristic dysfunction seen in chronic kidney disease. Kidney dysfunction arises from the interplay of metabolic and hemodynamic factors in kidney microcirculation. Molecular biological studies of the pathogenesis of kidney dysfunction will undoubtedly lead to the development of new promising approaches for preventing this pathology.

References

1. Samadova A. B. et al. PREVENTIVE AND DIAGNOSTIC SIGNIFICANCE OF ECG RESULTS IN PATIENTS WITH DIABETES MELLITUS //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2023. – Т. 1. – №. 9. – С. 36-39.

2. Ataxonovich J. A., Samadova A., Maratovna D. D. MODERN TREATMENT METHODS FOR HEPATORENAL SYNDROME //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 12. – С. 147-154.

3. Ataxonovich, Jabbarov Azimboy, and Shegay Olga Alekseyevna. "HEPATORENAL SYNDROME PREDICTORS OF CLINICAL, PATHOGENETIC, AND GENETIC FACTORS." *Western European Journal of Medicine and Medical Science* 2.12 (2024): 20-27.

4. Ruzmetov N. A., Samadova A. B., Abdullayev Q. F. DIAGNOSIS OF KIDNEY DAMAGE AND CHRONIC KIDNEY DISEASE AFTER LIVER DISEASES AMONG THE POPULATION OF KHOREZM REGION //Talqin va tadqiqotlar ilmiy-uslubiy jurnali. – 2024. – Т. 2. – №. 56. – С. 235-240.

5. Ismailov, K. Y., & Abdullaev, I. K. Research of the Distribution and Transmission of Covid-19 Infection. JournalNX, 686-691.

6. Ismailov, K. Y., & Djabbarova, Z. I. (2024). OBESITY AND ISCHEMIC HEART DISEASE. European Journal of Modern Medicine and Practice, 4(11), 364-367.

8.Абдуллаев Р. Б., Ходжаев Ш. А., Рузметова М. С. Распространенность экстрагенительных заболеваний у женщин фертильного возраста, проживающих в условиях экологического неблагополучия //Мед. журн. Узбекистана. – 2000. – Т. 4. – С. 65-67.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-3

9.Абдуллаев Р. Б. Особенности клинического течения, распространенности и новые подходы к лечению язвенной болезни желудка и двенадцатиперстной кишки в Южном Приаралье //Автореф. дисс.... докт. мед. наук. Ташкент. – 2002. – С. 15-23.

10.Sh, S. N., Shermetov, R. A., & Nurullayev, S. X. (2024). Nutritiology And Proper Nutrition. Texas Journal of Medical Science, 28, 21-23

11.Zokirxodjaev, S. Y., Shamuratova, N. S., Duschanov, B. A., & Xudayberganov, A. S. (2021). Fatty acid composition of grain sorghum lipids and justification of its use in diet therapy for chronic liver diseases. Central Asian Journal of Medicine, 2021(1), 58-63.

12.Kalandarova, G. D., & Sh, S. N. (2023). THE LAWS OF CORRECT DIET AND THE CONSEQUENCES OF IMPROPER DIET. Web of Medicine: Journal of Medicine, Practice and Nursing, 1(8), 64-67.

13.ШАМУРАТОВА, Н., РУЗИМОВ, Х., & РУЗМЕТОВА, Д. (2023). БИОЛОГИЧЕСКАЯ И ДИЕТИЧЕСКАЯ ЦЕННОСТЬ ЗЕРНОВОЙ ПРОДУКЦИИ СОРГО ПО АМИНОКИСЛОТНОМУ СОСТАВУ ПРИ НЕКОТОРЫХ ЗАБОЛЕВАНИЯХ.

14.Шомуротова, Н. Ш., Дусчанов, Б. А., Зокирходжаев, Ш. Я., & Рўзметова, Д. А. (2023). СУРУНКАЛИ ГЕПАТИТ БИЛАН ХАСТАЛАНГАН БЕМОРЛАРНИНГ ЁЗ-КУЗ МАВСУМИДАГИ КУНЛИК ОВҚАТЛАНИШ ТАРТИБИНИ ГИГИЕНИК БАҲОЛАШ.

15.ШАМУРАТОВА, Н., ЗОКИРХОДЖАЕВ, Ш., & ДУСЧАНОВ, Б. (2023). ПАРҲЕЗ ОВҚАТЛАНИШНИНГ ҚАНДЛИ ДИАБЕТДА САМАРАДОРЛИГИ.

16.Шамуратова, Н. Ш., Зокирходжаев, Ш. Я., & Рузметова, Д. А. (2023). ЖИГАРНИНГ СУРУНКАЛИ КАСАЛЛИКЛАРИДА ДИЕТОТЕРАПИЯДА МАҲАЛЛИЙ МАҲСУЛОТЛАР ҚЎЛЛАШНИНГ САМАРАСИ (Doctoral dissertation, UZBEK JOURNAL OF CASE REPORTS, Узбекистан). UZBEK JOURNAL OF CASE REPORTS, Узбекистан.